Age-related macular degeneration (AMD) Market is expected to showcase exceptional Growth by 2032

Age-related macular degeneration (AMD) Market is expected to showcase exceptional Growth by 2032 – Estimates DelveInsight | Key Companies- Roche, Opthea Limited, Apellis Pharma, IVERIC Bio, Novartis, & Others

Age-related macular degeneration (AMD) is a neurodegenerative disease of the aging retina, in which patients experience severe vision loss. AMD is one of the most prevalent ocular conditions in developed countries with more than 10 million US adults affected by AMD. Based on severity of the disease, It is of three stages: Early, Intermediate and Late-stage; Late stage AMD is of two types: Dry AMD and Neovascular AMD (nAMD).

AMD’s progression leads to loss of central vision, leaving many patients unable to read, write, or recognize both color and detail, thus compromising the quality of life. Although AMD’s exact functional pathogenesis is not fully understood, there have been recent improvements in genetic technologies leading to the identification of various polymorphisms that have shown to harbor unique associations with AMD. This has led to identification of many new targets for controlling disease progression.

Click here to Request for Age Related Macular Degeneration Market Sample Page:

DelveInsight's "Age Related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Age Related Macular Degeneration, historical and forecasted epidemiology as well as the Age Related Macular Degeneration market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some facts of Age-related macular degeneration (AMD) Market Report

  • According to Ayoub et al., Age-related macular degeneration (AMD) is the leading cause of blindness and visual disability in patients aged over 60 years in Europe and North America. It is the third leading cause of blindness, behind cataract and glaucoma, causing 8.7% of all legal blindness across the world.
  • Globally, around 20 million people are living with nAMD – the leading cause of cause of vision loss in people over the age of 60.
  • According to Braclay et al. (2021), based on types of AMD, dry AMD accounts for nearly 85-90% of the cases and Neovascular AMD (nAMD) accounts for only 10% of the cases, but nAMD is responsible for nearly 90% of the severe, central visual acuity loss associated with AMD.
  • According to Schwatz et al. (2021), dry AMD prevalence was reported as 0.44% globally, with similar or slightly higher values reported for wet AMD. Dry AMD prevalence varied across ethnic groups (1.11% European, 0.21% Asian, 0.16% Hispanic, and 0.14% African).
  • According to DelveInsight’s analysis, AMD is more prominent in females in comparison to males.
  • Among the age-specific cases of AMD, 61-70 years of age represents the biggest category, followed by 51-60 years of age.
  • The prevalence of AMD is poised to increase due to the increase in geriatric population in all 7MM.

Click here to Request for Age Related Macular Degeneration Market Sample Page:

Scope of the Age-related macular degeneration (AMD) Market Report

  • The report covers the descriptive overview of Age Related Macular Degeneration, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Age Related Macular Degeneration epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Age Related Macular Degeneration is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Age Related Macular Degeneration market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Age Related Macular Degeneration market.

Click here to Request for Age Related Macular Degeneration Market Sample Page:

Age-related macular degeneration (AMD) Companies are:

  • Roche
  • Opthea Limited
  • Apellis Pharma
  • IVERIC Bio
  • Novartis
  • Regeneron Pharmaceuticals
  • And Others

To get detailed insights into Age-related macular degeneration Pipeline therapies and companies working in the domain, Click here:

Age-related macular degeneration (AMD) Pipeline Drugs and Therapies:

  • Faricimab
  • OPT-302
  • APL-2
  • Beovu
  • Lucentis
  • Eylea
  • And Others

To get competitive insights into Age-related macular degeneration Pipeline, Click here:

Table of Content

  1. Key Insights
  2. Executive Summary 
  3. Age-related macular degeneration Competitive Intelligence Analysis
  4. Age-related macular degeneration Market Overview at a Glance
  5. Age-related macular degeneration Disease Background and Overview
  6. Age-related macular degeneration Patient Journey
  7. Age-related macular degeneration Epidemiology and Patient Population
  8. Age-related macular degeneration Treatment Algorithm, Current Treatment, and Medical Practices
  9. Age-related macular degeneration Unmet Needs
  10. Key Endpoints of Age-related macular degeneration Treatment
  11. Age-related macular degeneration Marketed Products
  12. Age-related macular degeneration Emerging Therapies
  13. Age-related macular degeneration Seven Major Market Analysis
  14. Attribute Analysis
  15. Age-related macular degeneration Market Outlook (7 major markets)
  16. Age-related macular degeneration Access and Reimbursement Overview
  17. KOL Views on the Age-related macular degeneration Market.
  18. Age-related macular degeneration Market Drivers
  19. Age-related macular degeneration Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.